This article was originally published in The Rose Sheet
Natural fragrance watchdog Cropwatch "has no confidence" in the ability of the European Commission's Scientific Committee on Consumer Products (SCCP) to assess the possible safety risks of tea tree oil, the group says in a Jan. 17 statement, with the tea tree oil dossier up for the committee's review Jan. 22 based on data submitted by the Australian Tea Tree Oil Industries Association in March 2007. Cropwatch cites alleged flaws in a 2004 opinion from the panel, which concludes that undiluted tea tree oil is not safe to use in commercial products, the stability of the oil in cosmetic formulations is "questionable" and that further tests to determine skin and eye irritation - among other endpoints - should be conducted. The watchdog alleges that SCCP did not take into account all available scientific evidence on tea tree oil in its report and that the predictions of adverse events from use of the oil were exaggerated. "Cropwatch calls for a review of the way that cosmetic ingredient safety is assessed by the regulator, since the existing [overly] precautionary principled approach is clearly failing the public," the group states....
You may also be interested in...
US Regulatory Roundup, June 2020: FDA Talks QSR Redo; ISO Risk Standard Gets Companion Doc; Experts Predict Recalls Surge; And More
News out of the US FDA on the harmonization of its Quality System Regulation with ISO 13485, as well as stories on a new ISO technical report on risk management and a warning from experts about probable recalls because of the COVID-19 pandemic, were of most interest to our readers last month. Here are June’s 10 most popular US regulation and policy stories from Medtech Insight.
The Bayesian adaptive trial design helped slash the Phase I time for Ridgeback’s drug, which could provide a pill-based alternative to Gilead’s remdesivir for COVID-19 patients.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.